Insulet Co. (NASDAQ:PODD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Insulet Co. (NASDAQ:PODD) has received a consensus recommendation of “Moderate Buy” from the seventeen analysts that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $292.06.

PODD has been the subject of a number of analyst reports. Raymond James reissued an “outperform” rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Canaccord Genuity Group increased their price target on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Citigroup boosted their price target on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Finally, TD Cowen increased their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd.

Insiders Place Their Bets

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now directly owns 3,231 shares of the company’s stock, valued at $888,525. This represents a 36.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Institutional Trading of Insulet

Institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC lifted its position in shares of Insulet by 1.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after buying an additional 42 shares in the last quarter. Horizon Investments LLC grew its position in shares of Insulet by 3.1% in the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 42 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Insulet by 1.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock worth $1,146,000 after purchasing an additional 43 shares in the last quarter. Glenmede Trust Co. NA raised its position in shares of Insulet by 2.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after purchasing an additional 47 shares during the last quarter. Finally, Graypoint LLC lifted its stake in Insulet by 5.3% in the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after buying an additional 47 shares in the last quarter.

Insulet Stock Down 4.5 %

Insulet stock opened at $245.26 on Friday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The firm has a market cap of $17.22 billion, a P/E ratio of 42.36, a P/E/G ratio of 3.62 and a beta of 1.30. The business has a fifty day moving average of $269.86 and a two-hundred day moving average of $259.53. Insulet has a twelve month low of $160.19 and a twelve month high of $289.46.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. On average, analysts forecast that Insulet will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.